Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533519 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)
A Phase 1 study, sponsored by James Murrough.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01533519 is a Phase 1 study that has completed, run by James Murrough. The registered enrollment target is 26 participants.
The verdict
NCT01533519, a Phase 1 study, has completed, sponsored by James Murrough.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety of intranasal administration of NPY using a dose escalation, randomized, double-blinded, placebo-controlled crossover design in a medication-free, symptomatic PTSD group.
Interventions
- DRUG Neuropeptide Y
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533519
The ClinicalTrials.gov registry entry for NCT01533519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Murrough, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neuropeptide Y is the first listed.
NCT01533519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533519 about?
NCT01533519 is a clinical study titled "A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)". This study is designed to investigate the safety of intranasal administration of NPY using a dose escalation, randomized, double-blinded, placebo-controlled crossover design in a medication-free, symptomatic PTSD group.
What is the current status of trial NCT01533519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01533519?
The interventions under investigation include: Neuropeptide Y (DRUG).
Who is sponsoring clinical trial NCT01533519?
This trial is sponsored by James Murrough, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.